Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Glasgow University, Glasgow, Scotland, United Kingdom



Survival: 19.8 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: United Kingdom
   
City/State/Province: Glasgow, Scotland
   
Hospital: Glasgow University
   
Journal: Link
   
Date: 4/2008

Description:
Patients: This phase III study involved 2,034 patients with metastatic colorectal cancer. There were 1,207 men and 827 women, and the majority (1,294) were under the age of 65. Most had not received previous adjuvant chemotherapy.

Treatment: Patients were treated with the one of four combinations of chemotherapy drugs: fluorouracil, folinic acid, and oxaliplatin; capecitabine and oxaliplatin, or one of these combinations with bevacizumab.

Toxicity: Forty-four percent of patients treated with fluoruracil, folinic acid, and oxaliplatin had grade 3/4 neutropenia/granulocytopenia, and 6.3% had venous thrombosis: these toxicities were more common in this group than the group of patients treated with capecitabine and oxaliplatin. Grade 3/4 neurosensory toxicity was reported in about 17% of patients. Bevacizumab did not have an effect on the difference in toxicities between the groups.

Results: The median overall survival of patients treated with fluoruracil, folinic acid, and oxaliplatin (with or without bevacizumab) was 19.6 months. The median overall survival of patients treated with capecitabine and oxaliplatin (with or without bevacizumab) was 19.8 months.

Support: This study was supported by Roche, which markets capecitabine (Xeloda“) and bevacizumab (Avastin“).

Correspondence: Dr. Jim Cassidy

E-mail to a Friend Email Physician More Information